184 related articles for article (PubMed ID: 30785963)
1. Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques.
Rosenberg YJ; Lewis GK; Montefiori DC; LaBranche CC; Lewis MG; Urban LA; Lees JP; Mao L; Jiang X
PLoS One; 2019; 14(2):e0212649. PubMed ID: 30785963
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.
Rosenberg Y; Sack M; Montefiori D; Labranche C; Lewis M; Urban L; Mao L; Fischer R; Jiang X
PLoS One; 2015; 10(3):e0120451. PubMed ID: 25807114
[TBL] [Abstract][Full Text] [Related]
3. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
[TBL] [Abstract][Full Text] [Related]
4. Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121.
Lee WS; Reynaldi A; Amarasena T; Davenport MP; Parsons MS; Kent SJ
Front Immunol; 2021; 12():749891. PubMed ID: 34867979
[TBL] [Abstract][Full Text] [Related]
5. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.
Gautam R; Nishimura Y; Pegu A; Nason MC; Klein F; Gazumyan A; Golijanin J; Buckler-White A; Sadjadpour R; Wang K; Mankoff Z; Schmidt SD; Lifson JD; Mascola JR; Nussenzweig MC; Martin MA
Nature; 2016 May; 533(7601):105-109. PubMed ID: 27120156
[TBL] [Abstract][Full Text] [Related]
6. A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.
Gautam R; Nishimura Y; Gaughan N; Gazumyan A; Schoofs T; Buckler-White A; Seaman MS; Swihart BJ; Follmann DA; Nussenzweig MC; Martin MA
Nat Med; 2018 May; 24(5):610-616. PubMed ID: 29662199
[TBL] [Abstract][Full Text] [Related]
7. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.
Julg B; Pegu A; Abbink P; Liu J; Brinkman A; Molloy K; Mojta S; Chandrashekar A; Callow K; Wang K; Chen X; Schmidt SD; Huang J; Koup RA; Seaman MS; Keele BF; Mascola JR; Connors M; Barouch DH
J Virol; 2017 Aug; 91(16):. PubMed ID: 28539448
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells.
Anand SP; Ding S; Tolbert WD; Prévost J; Richard J; Gil HM; Gendron-Lepage G; Cheung WF; Wang H; Pastora R; Saxena H; Wakarchuk W; Medjahed H; Wines BD; Hogarth M; Shaw GM; Martin MA; Burton DR; Hangartner L; Evans DT; Pazgier M; Cossar D; McLean MD; Finzi A
J Virol; 2021 Aug; 95(18):e0079621. PubMed ID: 34232070
[TBL] [Abstract][Full Text] [Related]
9. Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques.
Parsons MS; Lee WS; Kristensen AB; Amarasena T; Khoury G; Wheatley AK; Reynaldi A; Wines BD; Hogarth PM; Davenport MP; Kent SJ
J Clin Invest; 2019 Jan; 129(1):182-191. PubMed ID: 30475230
[TBL] [Abstract][Full Text] [Related]
10. Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques.
Rosenberg YJ; Montefiori DC; LaBranche CC; Lewis MG; Sack M; Lees JP; Jiang X
PLoS One; 2016; 11(3):e0152760. PubMed ID: 27031108
[TBL] [Abstract][Full Text] [Related]
11. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
[TBL] [Abstract][Full Text] [Related]
13. Improving the efficacy of plant-made anti-HIV monoclonal antibodies for clinical use.
Grandits M; Grünwald-Gruber C; Gastine S; Standing JF; Reljic R; Teh AY; Ma JK
Front Plant Sci; 2023; 14():1126470. PubMed ID: 36923134
[TBL] [Abstract][Full Text] [Related]
14. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
15. Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques.
Dennis M; Eudailey J; Pollara J; McMillan AS; Cronin KD; Saha PT; Curtis AD; Hudgens MG; Fouda GG; Ferrari G; Alam M; Van Rompay KKA; De Paris K; Permar S; Shen X
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541851
[TBL] [Abstract][Full Text] [Related]
16. Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection.
Parsons MS; Lloyd SB; Lee WS; Kristensen AB; Amarasena T; Center RJ; Keele BF; Lifson JD; LaBranche CC; Montefiori D; Wines BD; Hogarth PM; Swiderek KM; Venturi V; Davenport MP; Kent SJ
Sci Transl Med; 2017 Aug; 9(402):. PubMed ID: 28794282
[TBL] [Abstract][Full Text] [Related]
17. Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies.
Gardner MR; Fetzer I; Kattenhorn LM; Davis-Gardner ME; Zhou AS; Alfant B; Weber JA; Kondur HR; Martinez-Navio JM; Fuchs SP; Desrosiers RC; Gao G; Lifson JD; Farzan M
Mol Ther; 2019 Mar; 27(3):650-660. PubMed ID: 30704961
[TBL] [Abstract][Full Text] [Related]
18. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.
Xu L; Pegu A; Rao E; Doria-Rose N; Beninga J; McKee K; Lord DM; Wei RR; Deng G; Louder M; Schmidt SD; Mankoff Z; Wu L; Asokan M; Beil C; Lange C; Leuschner WD; Kruip J; Sendak R; Kwon YD; Zhou T; Chen X; Bailer RT; Wang K; Choe M; Tartaglia LJ; Barouch DH; O'Dell S; Todd JP; Burton DR; Roederer M; Connors M; Koup RA; Kwong PD; Yang ZY; Mascola JR; Nabel GJ
Science; 2017 Oct; 358(6359):85-90. PubMed ID: 28931639
[TBL] [Abstract][Full Text] [Related]
19. Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies.
Parsons MS; Chung AW; Kent SJ
Retrovirology; 2018 Aug; 15(1):58. PubMed ID: 30134945
[TBL] [Abstract][Full Text] [Related]
20. Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus.
Liu J; Ghneim K; Sok D; Bosche WJ; Li Y; Chipriano E; Berkemeier B; Oswald K; Borducchi E; Cabral C; Peter L; Brinkman A; Shetty M; Jimenez J; Mondesir J; Lee B; Giglio P; Chandrashekar A; Abbink P; Colantonio A; Gittens C; Baker C; Wagner W; Lewis MG; Li W; Sekaly RP; Lifson JD; Burton DR; Barouch DH
Science; 2016 Sep; 353(6303):1045-1049. PubMed ID: 27540005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
